Berkshire Hathaway Inc (BRK.A): Pshawww! I made the list! In the earl...

fung_derf · 2025-03-12T16:49:25.0230000Z

Pshawww! I made the list! In the early 1980s, Mr. Rakesh Jhunjhunwala began his investment journey by investing in small stocks. However, he had a strong investment philosophy which was based on heavy market research and a long-term approach to investment. This made him identify undervalued companies with strong growth potential

Play Episode

6min

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Proactive - Interviews for investors

Time Finance CEO on Q3 update: record lending & growth to resilient small businesses

Time Finance PLC (AIM:TIME) CEO Ed Rimmer takes Proactive's Stephen Gunnion through the company’s performance in the third quarter, highlighting a record gross lending book and improved arrears management. Rimmer explained that Time Finance provides funding solutions to small businesses, including invoice finance, asset finance, and secured loans, typically supporting businesses with turnover up to £10 million. He said, “We help businesses grow, but we also help businesses to survive as well.” The company’s lending book reached a record £210 million at the end of February, with arrears falling to 5% from 6% a year earlier. Rimmer noted this progress came despite challenging market conditions and was achieved without compromising credit quality. Margins have also increased, with profit margins now at 40%. This was attributed to tight cost control and improved efficiency, including leveraging technology and streamlining internal processes. Time Finance has not increased its headcount significantly post-COVID, which has helped support margin growth. Rimmer also addressed the broader economic environment, pointing to interest rate pressures, inflation, and increased insolvencies, but emphasised that small businesses remain resilient. The company sees opportunity as traditional banks become more risk-averse, creating space for independent lenders. Visit Proactive’s YouTube channel for more interviews like this. Don’t forget to like the video, subscribe to the channel, and enable notifications so you never miss an update. #TimeFinance #SMElending #AlternativeFinance #BusinessLoans #InvoiceFinance #AssetFinance #Q3TradingUpdate #IndependentLender #FinancialResults #SmallBusinessFinance

Proactive - Interviews for investors

Inspired PLC CEO Mark Dickinson breaks down FY24 highlights, net zero strategy

Inspired PLC (AIM:INSE) chief executive Mark Dickinson takes Proactive's Stephen Gunnion through the company's 2024 financial results, its ongoing mission to help clients reach net zero, and the outlook for 2025. Dickinson provided an overview of the group’s four complementary divisions: software, assurance, ESG, and optimisation. These work together to help Inspired’s B2B clients manage energy costs, comply with ESG reporting obligations, and implement real carbon reduction strategies. “The backdrop continues to be increasingly favourable for Inspired as we help those clients navigate their way through those challenges,” Dickinson said, citing continuing demand despite lower energy prices. FY24 was a year focused on strengthening the balance sheet. Dickinson said the company eliminated all contingent consideration liabilities, raised capital, and reduced net leverage from 2.59x to 1.47x adjusted EBITDA—giving the business a firmer platform for growth. The company’s non-financial KPIs also moved in a positive direction, with cross-selling increasing and more than 50% of optimisation clients returning for additional services. Inspired is now serving 420 clients with optimisation support. Looking ahead, Dickinson said trading in 2025 started in line with expectations, and the business is progressing well on previously delayed projects. He remains optimistic about the pipeline and demand drivers, particularly in energy conservation, ESG compliance, and net zero support. For more CEO interviews and company updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and enable notifications so you never miss an update. #InspiredPLC #NetZero #EnergyEfficiency #ESG #CarbonReduction #SustainabilityGoals #CleanEnergy #GreenBusiness #UKStocks #ProactiveInvestors

Proactive - Interviews for investors

Immunic CMO discusses significance of MS Awareness Month; progress with treatment

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s work in multiple sclerosis (MS) as MS Awareness Month concludes. Muehler discussed the importance of continued research funding and the community’s role in advancing treatment. He highlighted the company’s lead asset, vidofludimus calcium, which is in advanced-stage clinical trials. Results from the phase 2 EMPHASIS trial in relapsing-remitting MS showed a reduction of about three-quarters of new MRI lesions compared to placebo. Muehler said, “This is a very good value,” and pointed to biomarker data showing a strong, dose-linear suppression of neurofilament — a sign of nerve cell damage. A phase 3 program involving more than 2,000 patients is now underway, with data expected in 2026. In progressive MS, Immunic is close to reporting data from its phase 2 CALLIPER trial, having already seen positive biomarker signals at 24 weeks. Muehler addressed patients’ fears of disability, stressing the company’s commitment to tackling "progression independent of relapse activity (PIRA)", a key unmet need. He emphasized vidofludimus calcium’s dual mechanism — both anti-inflammatory and neuroprotective — and its potential to become the first oral drug targeting the full spectrum of MS. To hear more insights from Immunic and other biotech leaders, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #ImmunicTherapeutics #MultipleSclerosis #MSAwarenessMonth #vidofludimuscalcium #MSTreatment #ClinicalTrials #Neuroprotection #MSResearch #BiotechNews #ProgressiveMS #RelapsingMS #PIRA #DrugDevelopment

Followers	261
Posts	114421
Boards Moderated	15
Alias Born	08/30/2001

Volume:	1,894
Day Range:	695517.00 - 757492.82
Bid:
Ask:
Last Trade Time:	7:00:00 PM EDT
Total Trades:	1,792

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

BRK.A Detailed Quote

Recent BRK.A News

More BRK.A News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent BRK.A News

Go Ad-Free